Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ACIP's Support Of FDA-Approved Prevnar 13 Creates Opportunity For Larger Market

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approves Pfizer's Prevnar 13 vaccine and ACIP's recommendations set the stage for a broadened indication and a blockbuster product.

You may also be interested in...



Gilead Builds Adherence Trial and Behavior Profiling Data Into Truvada PrEP Approval

FDA approval of Gilead’s Truvada for pre-exposure prophylaxis generated national news in advance of the major HIV/AIDS international scientific meeting starting in Washington one week later. As part of the final negotiations to get the approval done in time for the news window, FDA and Gilead worked out an interesting arrangement on post-marketing studies that has broad implications for future sponsors.

Prevnar 13 Advisory Committee Review Moved Back To November

Revised schedule allows FDA to evaluate additional data on concomitant use of Pfizer's pneumococcal disease vaccine with flu vaccine for older adults, but could cause extra delays at CDC.

Prevnar 13 Advisory Committee Review Moved Back To November

Revised schedule allows FDA to evaluate additional data on concomitant use of Pfizer's pneumococcal disease vaccine with flu vaccine for older adults, but could cause extra delays at CDC.

Related Content

Topics

UsernamePublicRestriction

Register

PS070270

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel